NovoCure Limited NVCR
Regular-session close
After hours · Nov 20, 5:25 PM ET
- YTD
- -17.17%
- 1 year
- -6.54%
5D -0.93 (-7.99%)
- Market cap
- 1.25B
- Revenue (ttm)
- 725.39M
- Profit margin
- -16.78%
- EPS (ttm)
- -1.06
- Shares out
- 116.92M
- Forward P/E
- -14.72
- YTD return
- -17.17%
- 1-year return
- -6.54%
- 50-day average
- 14.40
- 200-day average
- 14.77
- Volume
- 1.64M
- Avg volume
- 1.51M
- Open
- 10.61
- Previous close
- 10.69
- Day's range
- 10.61 – 11.06
- 52-week range
- 9.82 – 21.45
- Beta
- 1.08
- Analysts
- Buy
- Price target
- 26.14 (+144.1%)
- Earnings date
- Feb 25, 2027
Key statistics
- Enterprise value
- 1.02B
- Price / sales
- 1.73
- Price / book
- 3.44
- Revenue growth
- 15.70%
- Free cash flow
- 9.00M
- Total cash
- 463.48M
- Total debt
- 231.55M
- Return on equity
- -35.19%
- Short % of float
- 14.91%
Fundamental scorecard
9 of 25 checks passed on NVCR’s reported financials
9of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 15.00
- Target (mean)
- 26.14
- Target (high)
- 52.00
- Strong buy1
- Buy3
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.214.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.23 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | -0.23487 | -0.09 | +0.14 | +61.68% |
| Jul 23, 2026 | Jun 30, 2026 | -0.33153 | -0.13 | +0.20 | +60.79% |
| Apr 30, 2026 | Mar 31, 2026 | -0.51219 | -0.62 | -0.11 | -21.05% |
| Feb 26, 2026 | Dec 31, 2025 | -0.41 | -0.22 | +0.19 | +46.34% |
| Oct 30, 2025 | Sep 30, 2025 | -0.42 | -0.33 | +0.09 | +21.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Ladenburg Thalmann | main | Buy | Buy |
| Nov 10, 2026 | Wedbush | main | Neutral | Neutral |
| Oct 30, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Jul 24, 2026 | Wedbush | main | Neutral | Neutral |
| Jul 23, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Switzerland
- Website
- novocure.com
News
Novocure Announces Upcoming Investor Events NovoCure Announces Publication Of Data Analysis From Phase 3 PANOVA-3 Trial
JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31
12 Health Care Stocks Moving In Tuesday's After-Market Session Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19
Novocure Stock Slips After FDA Rejects Its Cancer Treatment Device Novocure Receives Not Approvable Letter From FDA In Response To PMA Application For Optune Mya For Treatment Of Adult Patients With Brain Metastases From Non-Small Cell Lung Cancer Following Stereotactic Radiation
Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15
Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20
Your note
Sign in to keep a note on NVCR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEN ARYE BARAK | General Counsel | Stock Award(Grant) | Jun 29, 2026 | 243,752 |
| BRACKMANN CHRISTOPH | Chief Financial Officer | Sale | Nov 8, 2026 | 175,499 |
| CORDOVA ASHLEY | Former | Stock Award(Grant) | Feb 26, 2026 | 440,208 |
| DANZIGER ASAF | Director | Stock Award(Grant) | Jun 29, 2026 | 416,742 |
| DOYLE WILLIAM F | Officer and Director | Stock Award(Grant) | Mar 2, 2026 | 328,397 |
| LEONARD FRANCIS XAVIER II | Chief Executive Officer | Stock Award(Grant) | Jun 29, 2026 | 461,425 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.86% | 17,375,855 | 186.10M | Sep 29, 2026 |
| Blackrock Inc. | 10.15% | 11,863,861 | 127.06M | Sep 29, 2026 |
| Soleus Capital Management, L.P. | 8.06% | 9,425,776 | 100.95M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.55% | 6,493,767 | 69.55M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.21% | 4,923,982 | 52.74M | Sep 29, 2026 |
| Morgan Stanley | 4.02% | 4,697,120 | 50.31M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.02% | 5,874,496 | 62.92M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 3,490,920 | 37.39M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.36% | 2,762,752 | 29.59M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 2,521,417 | 27.00M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.49% | 1,741,745 | 18.65M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.33% | 1,550,900 | 16.61M | Sep 29, 2026 |
